In a post-hoc analysis of MADIT-II trial (patients ≥ 75 years), a tendency to an improved survival in the ICD group was found, although the benefit did not reach statistical significance.
1
—
—
In a post-hoc analysis of MADIT-II trial (patients ≥ 75 years), a tendency to an improved survival in the ICD group was found, although the benefit did not reach statistical significance.